Psychopharmacology Books

Book SynopsisObject Lessons is a series of short, beautifully designed books about the hidden lives of ordinary things. You are what you eat. Never is this truer than when we use medications, from beta blockers and aspirin to Viagra and epiduralsand especially psychotropic pills that transform our minds as well as our bodies. Meditating on how modern medicine increasingly measures out human identity not in T. S. Eliot's proverbial coffee spoons but in 1mg-, 5mg-, or 300mg-doses, Pill traces the uncanny presence of psychiatric pills through science, medicine, autobiography, television, cinema, literature, and popular music. Robert Bennett reveals modern psychopharmacology to be a brave new world in which human identities thoughts, emotions, personalities, and selves themselvesare increasingly determined by the extraordinary powers of seemingly ordinary pills.Object Lessons is published in partnership with an essay series in The Atlantic.Trade ReviewBennett is great … in showing how the pill has pervaded popular culture and popular thinking. He coins the genre title of “psychopharmacological thriller,” a mouthful but apt: the film or TV show about not just drugs, but also their making, distribution, and effects. Under this last head, he unleashes a brilliant set piece on Carrie Mathison (played so well by Claire Danes in Homeland.) * The Philadelphia Inquirer *Robert Bennett's Pill, another volume in Bloomsbury's fine Object Lessons series … effectively looks at all areas of the history, understanding, and application of pills as maintenance tools (or presumed cures) in psychopharmacology … It's this careful, methodical journey Bennett takes through these medications and their effects as manifested through popular culture that makes Pill an effective, compelling book … Pill succinctly and comprehensively charts the enigmatic relationship humanity has had with wonder drugs of all sorts, particularly here Thorazine through Adderall. [Bennett] suggests, carefully, and with touching immediacy (especially through the final personal chapter), that there's still work to be done as we understand both the blessings and the curses of these drugs. * PopMatters *In this wide-ranging and readable book, Robert Bennett shows the many ways that our pills are us. Pill is a cautionary tale about putting our faith in easy cures, and necessary reading for anyone who wants to better understand our complex, anxious, and uncertain times. * Rachel Adams, Professor of English and Comparative Literature, Columbia University, and author of Raising Henry: A Memoir of Motherhood, Disability, and Discovery (2013) *Adept in its understanding of the relationship between pharmacology and culture, this book incisively demonstrates how psychotropic drugs engineer the modern self. Pill doesn’t invite us to ask our doctors about Zoloft but rather to ask ourselves how Zoloft defines us as individuals. * Lorenzo Servitje, Assistant Professor of Literature and Medicine, Lehigh University, USA, and co-editor of The Walking Med: Zombies and the Medical Image (2016) *Table of ContentsIntroduction: Pharmageddon 1 Thorazine (C17H19ClN2S): The Psychopharmacological Revolution 2 Valium (C16H13ClN2O): The Psychopharmacology of Everyday Life 3 Lithium (Li2CO3): The Psychopharmacological Thriller 4 Prozac (C17H18F3NO): Existential Quagmires 5 Adderall ((C9H13N)2H2SO4 + (C9H13N)2H2SO4 + (C9H13N)2C6H10O8 + (C9H13N)C4H7NO4H2O): Psychopharmacology Unbound Coda: Waiting for Brad Pitt Acknowledgements List of Figures Notes Index

Read more less

Book SynopsisWe are on the cusp of a major revolution in psychiatric medicine and neuroscience. After fifty years of prohibition, criminalisation and fear, science is finally showing us that psychedelics are not dangerous or harmful. Instead, when used according to tested, safe and ethical guidelines, they are our most powerful newest treatment of mental health conditions, from depression, PTSD, and OCD to disordered eating and even addiction and chronic pain.Professor David Nutt, one of the world's leading Neuropsychopharmacologists, has spent 15 years researching this field and it is his most significant body of work to date. In 2018, he co-founded the first academic psychedelic research centre - underpinned by his mission to provide evidence-based information for people everywhere. It revived interest in the understanding and use of this drug in its many forms, including MDMA, ayahuasca, magic mushrooms, LSD and ketamine. The results of this have been nothing short of ground-breaking for the future categorisation of drugs, but also for what we now know about brain mechanisms and our consciousness.At a time where there is an enormous amount of noise around the benefits of psychedelics, this book contains the knowledge you need to know about a drug that is about to go mainstream, free from the hot air, direct from the expert.Are you ready to change your mind?

Read more less

Book SynopsisIn an era when more people are taking psychiatric drugs than ever before, Joanna Moncrieff's explosive book challenges the claims for their mythical powers. Drawing on extensive research, she demonstrates that psychiatric drugs do not 'treat' or 'cure' mental illness by acting on hypothesised chemical imbalances or other abnormalities in the brain. There is no evidence for any of these ideas. Moreover, any relief the drugs may offer from the distress and disturbance of a mental disorder can come at great cost to people's physical health and their ability to function in day-to-day life. And, once on these drugs, coming off them can be very difficult indeed. This book is a wake-up call to the potential damage we are doing to ourselves by relying on chemical cures for human distress. Its clear, concise explanations will enable people to make a fully informed decision about the benefits and harms of these drugs and whether and how to come off them if they so choose.Trade Review'This is a brilliant book. It offers an incisive, clear and evidence based appraisal of psychiatric drugs, arriving at just the right time to counter the growing controversy and confusion in this area. I could not think of a more respected and credible guide to take us through this tricky terrain. This book should be compulsory reading for anyone working in mental health. I would also recommend it for anyone holding a more personal interest in the subject.' - Dr James Davies, Reader in Social Anthropology & Mental Health, University of Roehampton, and author of Cracked: why psychiatry is doing more harm than good. 'There has never been a greater need for calm and reasoned thinking about psychiatric drug use, and, as a practising and open-minded psychiatrist, Joanna is the very best person to provide it. This book brings evidence and rationality to a contentious topic and offers people sound, researchbased information and genuine choice.' - Dr Lucy Johnstone, consultant clinical psychologist, author of A Straight Talking Introduction to Psychiatric Diagnosis and lead co-author of The Power Threat Meaning FrameworkTable of ContentsIntroduction, 1. The place of drug treatment in psychiatry, 2. How do psychiatric drugs work?, 3. The importance of research , 4. Antipsychotic drugs , 5. Antidepressants, 6. Lithium and other drugs used for bipolar disorder, 7. Stimulants, 8. Benzodiazepines, 9. Withdrawing from psychiatric drugs, 10. When might psychiatric drugs be useful? , 11. How did we get here and where do we go with it?, Appendix, Indexes

Read more less

Book SynopsisMost twentysomethings don't have disorders that need to be treated; they have problems that need to be solved.

Read more less

Book SynopsisOur twenties can be challenging. Today, so many twentysomethings are struggling, especially with anxiety and depression, and yet we're not sure what to think or do about it. In The Twentysomething Treatment psychologist Dr. Meg Jay explores why and unveils a ground-breaking approach that prioritizes skills over pills.As a seasoned clinical psychologist specialising in the unique challenges of this pivotal decade, Dr. Jay dismantles the myth that twentysomethings are fragile beings and explains why medication is sometimes, but not always, the best medicine.Within the transformative pages of this book, Dr. Jay provides practical solutions for a range of problems as she expertly guides readers through finding purpose and embracing uncertainty without unravelling. She offers actionable advice on navigating the intricacies of work, love, sex, friendship, confidence, health and happiness.The Twentysomething Treatment is not just a book; it''s a lifeline for a generation grappling with a ment

Read more less

Book SynopsisWhat actually happens to you when you drink a cup of coffee?Is chocolate really an aphrodisiac? How do drugs like alcohol and cannabis work? Did psychedelics play a part in human evolution? In this fascinating little book, leading psychopharmacologist Dr. Ben Sessa describes the drugs, legal and illegal, natural and synthesised, from nicotine to endorphins, sugar to antidepressants, that humans all over the world take every day to change their state of mind. "Fascinating" FINANCIAL TIMES. "Beautiful" LONDON REVIEW OF BOOKS. "Rich and Artful" THE LANCET. "Genuinely mind-expanding" FORTEAN TIMES. "Excellent" NEW SCIENTIST. "Stunning" NEW YORK TIMES. Small books, big ideas.Table of ContentsIntroduction 1 States of Consciousness 2 The Brain 4 Neurotransmitters 6 Oxytocin & Adrenaline 8 Dreaming 10 Hypnotic States 12 Meditation 14 Endorphins 16 Sex & Aphrodisiacs 18 Emotional States 20 Food & Fasting 22 Sugar 24 Chocolate 26 Caffeine 28 Alcohol 30 Nicotine 32 Cannabis 34 Solvents & Inhalants 36 Ketamine & Nitrous Oxide 38 Cocaine 40 Opiates 42 MDMA & Amphetamines 44 Natural Psychedelics 46 LSD 48 Poisons & Potions 50 Shamanism 52 Antidepressants 54 Quantum Consciousness 56 Further Reading 58

Read more less

Book SynopsisUnique in its breadth of coverage ranging from historical accounts of drug use to clinical and preclinical behavioral studies, Psychopharmacology is appropriate for undergraduates studying the relationships between the behavioral effects of psychoactive drugs and their mechanisms of action. BL Chapter-opening vignettes foster student engagement BL Up-to-date and outstanding coverage of current research BL Breakout boxes present novel, and, in some cases, controversial topics for special discussion. Box themes include History of Psychopharmacology; Pharmacology in Action; Clinical Applications; Of Special Interest; and The Cutting Edge BL The book is extensively illustrated with full-color photographs and line art depicting important concepts and experimental data BL Section Summaries highlight key concepts from the section of text just read BL Chapter-ending Recommended Readings offer suggestions for further study BL Enhanced e-Book provides an interactive learning pathway through the content BL End-of-chapter study questions to further aid students Meyer, Psychopharmacology and it's accompanying enhanced ebook provide engaging features like self-study questions, and clinical case studies, cutting edge research, and applied pharmacology to keep students focused on the content, while providing the scientific depth, breadth, and rigor required for the course.

Read more less

Book Synopsis'Poignant and lyrical...Slater's experience makes her a convincing travel guide into the history, creation and future of psychotropics.' – The New York Times Book Review A groundbreaking and revelatory story of the psychotropic drugs that have shaped our minds and our reality.  As our approach to mental illness has oscillated from biological to psychoanalytical and back again, so have our treatments. With the rise of psychopharmacology, an ever-increasing number of people throughout the globe are taking a psychotropic drug, yet nearly seventy years after doctors first began prescribing them, we still don’t really know exactly how or why they work – or don’t work – on what ails our brains. In The Drugs that Changed Our Minds, Lauren Slater offers an explosive account not just of the science but of the people – inventors, detractors and consuTrade Review'A profound and essential look at a phenomenon of our times. Meticulously researched, The Drugs That Changed Our Minds is also a deeply moving personal investigation into the drugs so many of us rely upon for our survival. Slater is much more than a trusted guide: she’s a brave and eloquent companion who doesn’t shy away from controversy. You’ll be talking and thinking about The Drugs That Changed Our Minds long after you’ve read it.' -- Terri Cheney, author of the New York Times bestseller Manic'In this ambitious undertaking, psychologist Slater applies vigorous research and intimate reflection to the issues involved with treating mental suffering...highly compelling' * Kirkus *'Weaving together the history of psychopharmacology and her personal experience as a patient, Slater offers readers a candid and compelling glimpse at life on psychiatric drugs and the science behind them. Intriguing and instructive.' * Booklist *'Psychologist Slater runs through the checkered history of psychopharmacology and mental illness treatments while sharing her own battle with depression and medication in this ambitious work . . . Slater offers many insights here, and her moving personal story truly illuminates the triumphs and shortcomings of psychotropic drugs.' * Publishers Weekly *'Slater, a writer and psychologist, takes a skeptical yet compassionate approach to the history of Psychopharmacology…the result is a vivid and thought-provoking synthesis' -- Lidija Haas * Harper’s Magazine *'the messy history and brave future of psychotropic drugs...Slater sifts through the remedies one in five Americans relies on but knows little about – even breaking into an abandoned asylum in her quest' * O Magazine *'A capacious and rigorous history...The real strength of this book comes from Slater’s very particular position. She is patient and psychologist, part of the first wave of people who were prescribed Prozac in the 1980s.' * New York Times *

Read more less

Book SynopsisA stimulating account of interest to all students of neuroscience, psychiatry, psychology or biology — and of immense value to ‘first timers’ including undergraduates and A-level students. Written by one of the UK’s leading brain science experts, it traces the relationship between the ions, membranes and pumps of the brain and our thoughts, senses, feelings, impulses and consciousness. The book deals with such tantalising questions as: What are the ‘locks and keys’ of the brain? How does memory work and why do we forget? Why do we sleep, dream, and hopefully wake-up ready to go? How do fears, threats and nightmares penetrate our mental defences, or drugs, alcohol, psychedelics and medicines improve or hinder our thoughts, actions or behaviour? Are our eyes connected to the brain and why do we sometimes see things that aren’t there? Or hear ‘voices’? The book also explains how we can ‘see inside’ the brain, why we sometimes make a fool of ourselves, may have near death experiences and whether epilepsy is an ‘affliction of the Gods.’ Similarly what scientists know about the differences between delusion and schizophrenia; or the links between worry, anxiety, depression, mania and euphoria. It also covers obsession, stress and repetitive behaviour — just some of many topics dealt with within its revealing pages. An expert, scientific but simple guide.Table of ContentsThe Origins of Our Brains — Ions, Membranes and Pumps; Neurotransmitters and their Receptors — The Locks and Keys of Brain Function; The Tower of Complexity — How the Brain is Organized; The Vital Role of Subconscious Processing; How the Cortex Works — Seeing is Believing; Taking Control — From Urges to Self-discipline; Thinking, Feeling and Consciousness; The Emotional Brain; Getting Inside the Head — Surgery to Imaging Techniques; Sleep and Dreams; In Extremis — Near Death Experiences and Vegetative States; Affliction of the Gods? — Epilepsy; Darkness Visible? Depression; Why Worry? Fear and Anxiety Disorders; Delusional? Schizophrenia and Mania; Repetition, Obsession and Compulsion; From Pleasure to Pain? Addiction; Brain and Mind or Brain-v-Mind?; Selected Bibliography; Index.

Read more less

Book SynopsisReal-world and clinical trial data support that clozapine is the only effective antipsychotic for treatment resistant schizophrenia and other severe mental illnesses. Clozapine also reduces rates of suicidality, psychiatric hospitalization and all-cause mortality. However, clozapine is underutilized for two reasons: misunderstandings of its efficacy benefits and misapprehension of, limited knowledge or misinformation about the management of treatment related risks and adverse effects. In response to worldwide efforts to promote clozapine use, this user-friendly Handbook provides clinicians with evidence-based approaches for patient management, as well as logical approaches to the management of clinical situations and adverse effects. It outlines clearly the rationale for specific management decisions and prioritises the options based on this logic. This Handbook is designed for use by clinicians worldwide and is essential reading for all mental health care professionals.Table of ContentsPreface; 1. Initiating Clozapine; 2. Understanding hematologic monitoring and benign ethnic neutropenia; 3. Binding profile, metabolism, kinetics, drug interactions and use of plasma levels; 4. Managing constipation; 5. Managing sialorrhea; 6. Managing sedation, orthostasis and tachycardia; 7. Managing metabolic adverse effects; 8. Managing seizure risk and stuttering; 9. Fever, myocarditis, interstitial nephritis, DRESS, serositis and cardiomyopathy; 10. Eosinophilia, leukocytosis, thrombocytopenia, thrombocytosis, anemia, hepatic function abnormalities; 11. Managing enuresis and incontinence, priapism, venous thromboembolism, neuroleptic malignant syndrome, tardive dyskinesia and obsessive compulsive disorder; 12. The efficacy story: treatment resistant schizophrenia, psychogenic polydipsia, treatment intolerant schizophrenia, suicidality, violence, mania and Parkinson's disease psychosis; 13. Addressing clozapine positive symptom nonresponse in schizophrenia spectrum patients; 14. Discontinuing clozapine and management of cholinergic rebound; 15. Special topics: child and adolescent patients, elderly patients, patients with intellectual disability, pregnancy and risk for major congenital malformation, lactation, overdose, postmortem redistribution; Index.

Read more less

Book SynopsisA classic in its field, Child and Adolescent Clinical Psychopharmacology Made Simple offers everything you need to know about the use of psychoactive medications in the treatment of childhood and adolescent psychological disorders in easy-to-understand language.This fully revised and updated fourth edition offers new information on sleep disorders, sleep medication, and substance abuse. You’ll also find up-to-date DSM-5 definitions, information regarding teen use of antidepressants and suicidality, attention deficit/hyperactivity disorder (ADHD) and ADHD medications, bipolar disorder, psychotic episodes and eating disorders in children and adolescents, the use of antipsychotics in children and adolescents, non-medication approaches and adjuncts to medications, and how to assess and treat noncompliance and “breakthrough” symptoms.Also included are fact sheets that clearly delineate frequently prescribed medications for each disorder along with medication side effects and signs of toxicity. For each psychological disorder, the book offers: current diagnostic criteria; treatment indications and contraindications; medication information; and help for monitoring, evaluating, and following up with patients.Whether you are a pediatrician, parent, therapist, educator, or other health care professional, this is the only resource you need to consult for the most recent information on child and adolescent medications and treatment.

Read more less

Book SynopsisLearn all the basics of psychedelics and why all this research is great news for public health in this century.After a very long and strange journey, psychedelics may finally be back for good. Rick Doblin, PhD, Founder & Executive Director, MAPS. In the guide you will learn all the essentials about the history, neuroscience, legality, therapeutic applications and harm reduction of the most promising psychedelic drugs for science. After decades of international prohibition these molecules are returning to laboratories and clinics, hand in hand with the most rigorous science, to revolutionize the way we understand and treat mental health (depression, anxiety, PTSD and addictions). Discover the world of psilocybin, MDMA, DMT, ketamine and LSD, before society immerses in this revolution, which will forever change the perception we have of psychedelics. This guide will be of interest to both therapists and other mental health professionals interested in the clinical applications, parents and educators seeking to understand the impact and safety of psychedelics and other drugs, as well as any adult curious to learn about and explore this new world of the psychedelic renaissance.

Read more less

Book Synopsis

Read more less

Book SynopsisThis spin-off from Stephen M. Stahl''s new, completely revised, and fully updated sixth edition of the Prescriber''s Guide covers the most important drugs in use today for treating patients suffering from psychotic illness. Now established as the indispensable formulary in psychopharmacology, easy to navigate and easy to use, the Prescriber''s Guide combines evidence-based information with clinically informed guidance to support clinicians in making the most effective prescribing decisions for the good of their patients. Incorporating information on the newest indications, new formulations, new recommendations and new safety data, this edition continues to provide the essential practical support required by anyone prescribing in the field of mental health.Table of ContentsIntroduction; List of icons; 1. Amisulpride; 2. Aripiprazole; 3. Asenapine; 4. Blonanserin; 5. Brexpiprazole; 6. Cariprazine; 7. Chlorpromazine; 8. Clozapine; 9. Cyamemazine; 10. Flupenthixol; 11. Fluphenazine; 12. Haloperidol; 13. Iloperidone; 14. Loxapine; 15. Lurasidone; 16. Mesoridazine; 17. Molindone; 18. Olanzapine; 19. Paliperidone; 20. Perospirone; 21. Perphenazine; 22. Pimavanserin; 23. Pimozide; 24. Pipothiazine; 25. Quetiapine; 26. Risperidone; 27. Sertindole; 28. Sulpiride; 29. Thioridazine; 30. Thiothixene; 31. Trifluoperazine; 32. Ziprasidone; 33. Zotepine; 34. Zuclopenthixol; Index by drug name; Index by use; Abbreviations.

Read more less

Book SynopsisNow in vibrant full color, Kaplan and Sadock’s Pocket Handbook of Psychiatric Drug Treatment, 8th Edition, remains your reference of choice for easy-to-find information on the full spectrum of psychiatric drug therapies. Written by Dr. Samoon Ahmad, this trusted resource provides a wealth of data for each drug, presenting information in a clear, concise manner for quick, efficient retrieval. This edition brings you fully up to date in the field, with new information on cannabis, psychedelics, psychotropic medicines and medical comorbidities, genetics and pharmacogenomics testing, and more. Includes new chapters on cannabis; psychedelics such as psilocybin, MDMA, and ketamine; and genetics and the role of pharmacogenomics testing, brain stimulation, and other novel technologies in psychiatry Includes many new FDA-approved drugs, as well as updated information about drug selection and use that reflects both research data and clinical experience Addresses the complex relationship between the use of psychotropic medicines and medical comorbidities, including metabolic complications, with emphasis on recognition, investigations, treatment, and management Features a new, full-color format with color icons that highlight side effects, notable benefits, and other important indications for each drug Provides a wealth of data for each drug: chemical name; preparation and dosages; pharmacologic actions; indications for use and clinical applications; use in children, elderly persons, and pregnant and nursing women; side effects and adverse and allergic reactions; and drug-drug interactions Ideal for psychiatrists and other physicians, as well as psychiatric residents, medical students, clinical psychologists, psychiatric nurses, and other professionals who provide care for patients with mental illness Enrich Your eBook Reading Experience Read directly on your preferred device(s), such as computer, tablet, or smartphone. Easily convert to audiobook, powering your content with natural language text-to-speech.

Read more less

Book SynopsisFinancial Times Business Top Title March 2022How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma, one of the world''s most breathtakingly expensive and highly regulated industries?Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. Moreover, they have done so with much lower overall costs. From Breakthrough to Blockbuster: The Business of Biotechnology focuses on both the companies themselves and the broaTrade ReviewWritten with authority * Financial Times *A fascinating guide to the complex business of biotechnology, with deep insights into the key factors, players, interactions and behaviors that have shaped the success of this industry. Suitable as a primer for those with no knowledge of the field, or as a refresher for the cognoscenti. Trigger warning: contains material that may distress pharma management * Sir Gregory Winter FRS, Trinity College, Cambridge University, recipient of 2018 Nobel Prize in Chemistry *A must read for all biotechnology leaders, this is a state-of-the-art analysis of the industry from two of its most successful entrepreneurs and a top business school professor, bringing rigor and actionable insight. * Dr Richard Mason, CEO of Apollo Therapeutics and former head of Johnson & Johnson's London Innovation Center *How is it possible that a few thousand small companies, many of them short-lived, can out-compete the mighty pharma majors at their own game? Understanding this puzzle is of fundamental importance for industry leaders and policy makers alike. This marvelous insider analysis is a must-read. * Stefan Scholtes, Dennis Gillings Professor of Health Management, Cambridge University Centre for Health Leadership & Enterprise *A remarkable synthesis and analysis of the Biotech industry that is a must-read for those trying to develop new life-saving medicines. * Margaret A. Liu, M.D., DSchc, MDhc, FISV, CEO of Pax Therapeutics, and board member, Ipsen, S.A. *Anyone who wants to understand how to leverage ecosystems for innovation in the face of uncertainty must read this rigorous analysis of how biotech companies, investors, government and big pharma have worked together to achieve some of the biggest scientific and commercial breakthroughs of the last century. * Arnoud De Meyer, Professor Emeritus and former President, Singapore Management University *A must read for everybody interested in the medical biotech industry, practically relevant and theoretically sound. * Jürgen Mihm, , Professor of Technology and Operations Management at INSEAD *An outstanding overview of the science and the business of innovative drugs. Students, researchers and policy makers will be immensely benefited from this book. * Mahmud Hassan, Ph.D, Professor and Director, Pharmaceutical Management Program, Rutgers Business School *Table of ContentsList of Figures and Tables Preface Chapter 1: Following the Map of the Genome Chapter 2: The Molecules Chapter 3: The Costly Drug Development Process Chapter 4: The Companies Chapter 5: Biotech-Pharma Alliances Chapter 6: The Biotech Entrepreneur Chapter 7: The Biotech Industry Track Record Chapter 8: The Future of the Biotech Industry Appendix 1 Appendix 2 Bibliography Index About the Authors

Read more less

Book SynopsisCognitive Behavioral Therapy for Preventing Suicide Attempts is a practical, clinician-friendly, how-to guide that demonstrates how to effectively reduce the risk for suicide attempts in any setting. Trade Review"I learned a lot from reading this book. From emergency and inpatient settings to the military environment and beyond, Cognitive-Behavioral Therapy for Preventing Suicide Attempts gets down to the nitty gritty of working with people at significant risk of suicide. Firmly based in research, yet clinically rich, this book is a veritable Swiss Army knife of suicide prevention manuals. Essential reading for all mental health clinicians, regardless of therapeutic orientation." Thomas E. Ellis, PsyD, ABPP, director of psychology at the Menninger Clinic and professor of psychiatry and behavioral science at the Baylor College of Medicine"This landmark text is a superb contribution to clinical suicidology. Expertly edited, it includes chapters from an all-star lineup of the field’s top authorities on CBT for suicide and deftly covers a range of views on cognitive-behavioral treatments for suicidal risk across a variety of clinical settings. It’s an indispensable book on a proven approach for effectively treating suicidal risk, and it will undoubtedly help save lives." David A. Jobes, PhD, ABPP, professor of psychology and associate director of clinical training at the Catholic University of America, Washington DC"There is an unfortunate shortage of evidence-based interventions and guidance for those working with patients at risk of suicide. This book is both practical and extremely helpful. Dr. Bryan and his colleagues are to be commended for meeting the needs of clinicians in multiple treatment settings." Timothy W. Lineberry, MD, former board chair of the American Association of Suicidology and former medical director of the Mayo Clinic Psychiatric HospitalTable of ContentsIntroduction Craig J. Bryan Section I: Understanding Suicide 1. The Problem of Suicide Michael D. Anestis and Lauren R. Khazem 2. The Language of Suicide Bridget B. Matarazzo, Beeta Y. Homaifar, Samantha A. Farro, and Lisa A. Brenner 3. What We Know and Don’t Know About Treating Suicide Risk Ann Marie Hernandez Section II: The Cognitive Behavioral Model of Suicide 4. A Cognitive Behavioral Model of Suicide Risk Tracy A. Clemans 5. Cognitive Therapy for Suicide Prevention: An Illustrative Case Example Kelly L. Green and Gregory K. Brown Section III: Suicide Prevention in Different Settings 6. Treating Risk for Self-Directed Violence in Inpatient Settings Marjan Ghahramanlou-Holloway, Laura L. Neely, and Jennifer Tucker 7. Preventing Suicide Attempts in Military Settings Craig J. Bryan and M. David Rudd 8. Treating Suicide Risk in Emergency Departments Emily Biggs, Cemile Ceren Sonmez, and Barbara Stanley 9. Treating Self-Directed Violence in Primary-Care Settings Craig J. Bryan and Peter C. Britton Section IV: Special Issues Special Issues with Treating Suicidal Patients Craig J. Bryan

Read more less

Book SynopsisTable of ContentsSection 1 Management of the psychoses 2 The antipsychotics 3 Antipsychotic side effects and their management References Section 2 Management of depression 4 The antidepressants 5 Side effects of antidepressants References Section 3 Management of bipolar disorders 6 Management of acute bipolar disorder 7 Mood-stabilisers References Section 4 Stimulants & Drugs for children 8 Stimulants & Drugs for children References Section 5 Management of anxiety 8 The anxiety disorders 10 Benzodiazepine anxiolytics 11 Anxiolysis and the serotonin system 12 Beta-blockers and anxiety References Section 6 Management of sleep disorders and insomnia 13 Sleep disorders and insomnia 14 Non-pharmacological management of insomnia 15 Hypnotics 16 Sedatives References Section 7 Management of cognitive impairment 17 Cognitive enhancement and the dementias 18 Cognitive enhancement and neuroprotection References Section 8 Management of sexual difficulties 19 The range of sexual difficulties 20 Effects of drugs on aspects of sexual functioning Appendix 20.1 Male sexual functioning questionnaire Appendix 20.2 Female sexual functioning questionnaire References Section 9 Management of dependence and withdrawal 21 Dependence & Withdrawal 22 Dependence & Craving 23 Dependence & Protracted Withdrawal References Section 10 Consent, abuse and liability 24 Consent 25 Pharmacological abuse References Section 11 The marketing of tranquillity 26 The ethical industry 27 Evidence-biased care 28 Marketing & Risk 29 From healthcare to pharmageddon

Read more less

Book SynopsisThe fourth volume in Stahl's Case Studies series describing the approach, diagnosis, and treatment of children and adolescents with psychiatric disorders. Demonstrating core principles that allow clinicians to individualize treatment and engage families, creating the best outcomes. Essential reading for mental health professionals and students.Trade Review'This collection of case studies is the most comprehensive and clinically relevant that I have ever read. As a practicing Child and Adolescent Psychiatrist, I have come face to face with many of the same clinical presentations and found Dr Strawn's review of the management thoughtful and integrative. It provides a unique framework for approaching these difficult interactions and offers a glimpse into how to combine science with the art of psychopharmacology when the evidence base is lacking. The emphasis on unique child and adolescent disorders, family dynamics and developmental pharmacology, outlines not just what the patient may need but also why. This is a must have for any Child and Adolescent Psychiatrist's library. I will certainly use it when teaching my residents and fellows and in my own practice as well.' Nicole M. Ballinger, DO, MPH, FAPA, Medical Staff President/Director, Child and Adolescent Psychiatry, Aurora Psychiatric Hospital, Wauwatosa, WI'Drs. Strawn and Stahl have really done it! The case-based teaching format and dozens of easy-to-read graphs and illustrations, walks clinicians of all levels through the complex world of pediatric psychopharmacology. Using easy-to-follow color-coded backgrounds and icons, the cases illustrate the evolution of each patient's treatment, the interplay of science and clinical wisdom, and the common pitfalls in the practice of pediatric psychopharmacology. In this era of rapidly advancing knowledge, this book provides a foundation rooted in the latest clinical pharmacology literature; it is a must-read for anyone practicing pediatric psychopharmacology.' John T. Walkup, M.D., Margaret C. Osterman Professor of Psychiatry Chair, Pritzker Department of Psychiatry and Behavioral Health; Ann and Robert H. Lurie Children's Hospital of Chicago; President-Elect, American Academy of Child & Adolescent Psychiatry'This book walks with you hand-in-hand as it describes common clinical challenges encountered while psychiatrically treating a child or adolescent. This is a must-have for novice and experienced clinicians alike, to provide clear guidance on ways to address a wide range of clinical scenarios affecting youth. In today's complex and burdened healthcare environment, this essential psychopharmacology for child and adolescent psychiatry gives the busiest clinicians readily available tools to navigate complex scenarios with clear, sequential, and logical guidance. The clinical pearls are written in pragmatically and with adult learning principles in mind. Thank you, Drs Stahl and Strawn, for capitulating the wisdom of our field in such an accessible and engaging way.' Manpreet Kaur Singh, M.D., M.S., Associate Professor of Psychiatry and Behavioral Sciences, Stanford University, StanfordTable of ContentsIntroduction; List of icons; Abbreviations; 1. The case: the salutatorian who couldn't speak: Selective Serotonin Reuptake Inhibitor (SSRI)-refractory anxiety in an adolescent; 2. The case: from anxious to activated: Selective Serotonin Reuptake Inhibitor (SSRI)-related activation; 3. The case: the girl who couldn't sleep: Posttraumatic Stress Disorder (PTSD) in a young girl; 4. The case: depressed and still depressed: Major Depressive Disorder (MDD) in an adolescent; 5. The case: a 13-year-old adolescent who feels 'amazing': Selective Serotonin Reuptake Inhibitor (SSRI)-induced mania in an adolescent; 6. The case: counting on a cure: Obsessive–Compulsive Disorder (OCD) in an adolescent; 7. The case: struggles in the second grade: Attention-Deficit Hyperactivity Disorder (ADHD) in a child; 8. The case: from prodrome to psychosis: early-onset schizophrenia; 9. The case: too much, too little, or just right? lithium dosing in an adolescent; 10. The case: tic, tic, tic: motor and vocal tics in a boy; 11. The case: how slow can you go? Selective Serotonin Reuptake Inhibitor (SSRI) withdrawal and discontinuation in an adolescent; 12. The case: the adolescent who doesn't eat: anorexia nervosa in an adolescent; 13. The case: high or higher antidepressant concentrations? cannabis-related drug interactions in an adolescent; 14. The case: the boy whose bed was always wet: nocturnal enuresis in a child; 15. The case: counting sheep and counting treatment trials: insomnia disorder in an adolescent; 16. The case: Second-Generation Antipsychotics (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with Autism Spectrum Disorder (ASD); 17. The case: the 'standard treatment' is earning a 'D': treatment-resistant schizophrenia; 18. The case: symptoms, side effects, or both? Selective Serotonin Reuptake Inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent; Index.

Read more less

Book Synopsis

Read more less

Book SynopsisUpdated to include a succinct yet thorough review of the most recent evidence-based information and data-driven best treatment practices in child and adolescent psychiatry, this fourth edition of the Clinical Manual of Child and Adolescent Psychopharmacology not only examines the evidence for treating mental health disorders in younger patients but also illuminates how clinical trials of various methodologies can inform different aspects of clinical practice. Organized by DSM-5-TR diagnosis rather than drug class, this clinically accessible volume offers an exhaustive analysis of the use of psychotropic agents in disorders that include • Attention-deficit/hyperactivity disorder• Depressive disorders• Autism spectrum disorder• Early schizophrenia and psychotic illnesses• Eating disorders Comprehensive medication tables allow for easy reference of dosing, side effects, and tips for management. Additionally, key points at the conclusion of each chapter summarize essential information for treating clinicians. With a depth of information unmatched by any other guide, this new edition of the Clinical Manual of Child and Adolescent Psychopharmacology is an indispensable desktop reference for clinicians working with young patients.Table of ContentsForewordPrefaceChapter 1. Developmental Aspects of Pediatric PsychopharmacologyChapter 2. Attention-Deficit/Hyperactivity DisorderChapter 3. Disruptive Behavior Disorders and AggressionChapter 4. Anxiety DisordersChapter 5. Major Depressive DisorderChapter 6. Bipolar DisordersChapter 7. Autism Spectrum DisorderChapter 8. Tic DisordersChapter 9. Early-Onset Schizophrenia and Psychotic IllnessesChapter 10. Eating Disorders

Read more less

Book SynopsisFrom insulin comas and lobotomy to incarceration; those who suffered bipolar disorder endured dangerous, ineffective treatments for centuries until a breakthrough in the 1950s offered salvation. Lithium’s efficacy at both ending and preventing manic depressive episodes was discovered by John Cade, whose years running a psychiatric ward as a prisoner of war sparked a hunch that put him on the path to revelation. The miraculous metal has since salvaged an untold number of lives but even after its healing power was discovered, it was decades before the medical community could be convinced that lithium was not only safe but life-saving. Walter A. Brown reveals how close we came to missing out on this extraordinary drug and showcasing the possibilities of scientific curiosity.Trade Review"The intertwined story of Cade and his momentous finding is told in Lithium, a compelling book by US psychiatrist Walter Brown... What Brown does superbly well is to show that Cade made his discovery without access to advances in technology or to modern facilities — and almost despite them." -- Nature"His [Walter Brown's] beautifully written and insightful book deserves to be widely read by poets and novelists, among whom instances of bipolar disorder are above average, and, more importantly, by all those involved in the regulation and provision of medicines." -- Literary Review

Read more less

Book SynopsisA comprehensive resource for mental health professionals-now in a fully revised and updated tenth edition.

Read more less

Book SynopsisA scientific guide to psychedelic-assisted mental health treatment

Read more less

Book SynopsisTHE DEFINITIVE GUIDE TO CANNABIS AND YOUR HEALTHUnderpinned by his two-year research trial in partnership with the Royal College of Psychiatrists, involving up to 20,000 patients, which will create Europe's largest body of evidence on the plant's medicinal qualities - Professor David Nutt and his team of scientists will break the mould on the way we use Cannabis for our health in the future.In David's first ground-breaking book on the subject, he will cover its impact of all areas of the body and the brain and its effective use for treatment of illness from chronic pain, epilepsy, multiple sclerosis and PTSD, to anxiety and depression. This is the essential knowledge that cuts through the noise and give us evidence-based information that will change people's lives.

Read more less

Book SynopsisSuccinct, authoritative, and affordable, Kaplan & Sadock’s Concise Textbook of Psychiatry, 5th Edition, provides must-know information in clinical psychiatry from the names you trust. From cover to cover, it contains the most relevant clinical material from the bestselling Kaplan and Sadock’s Synopsis of Psychiatry, 12th Edition, including the foundational chapters on assessment, the disorder specific chapters, and all of the treatment-specific chapters among other essential topics such as emergency psychiatry, ethics, and palliative/end-of-life care. New editors Robert Boland and Marcia L. Verduin, along with consulting editor Pedro Ruiz, have updated all content with a focus on reformatting and summarizing for faster access to key information. Provides concise but thorough coverage of the entire field of clinical psychiatry, including biologic, psychologic, and sociologic factors in health and disease. Offers step-by-step guidance on the clinical examination, the psychiatric report, medical assessment of the psychiatric patient, laboratory tests, and signs and symptoms, as well as all psychiatric and substance-related disorders, with special chapters on children, adolescents, and the elderly. Presents the most current treatment methods including descriptions of all modern psychotherapeutic techniques. Contains real-world case histories throughout and features a unique glossary of psychiatric signs and symptoms. Includes thorough updates and revisions throughout, all consistent with the DSM-5. Presents a comprehensive overview of the clinical aspects of psychiatry for clinicians, residents, students, and all others who provide mental health care. , Enrich Your eBook Reading Experience Read directly on your preferred device(s), such as computer, tablet, or smartphone. Easily convert to audiobook, powering your content with natural language text-to-speech. ,

Read more less

Book SynopsisIn his latest book, science writer and medicinal chemist Jie Jack Li guides readers through the history of viruses, vaccines, and antiviral drugs. Li chronicles the discovery and treatment of HIV/AIDS, hepatitis, influenza, and coronaviruses. Throughout, Li focuses on how viruses have shaped human history and on the individuals who developed treatments.Table of ContentsPreface Chapter 1. Virus Shaping History and Discovery of Virus 1.1 Virus shaping history 1.1.1 Tulipomania: bubbles of bulbs 1.1.2 The fall of old Mexico and Peru 1.1.3 Succession of thrones 1.1.4 The Louisiana Purchase 1.2 Discovery of virus 1.2.1 The gem theory 1.2.2 Discovery of virus 1.2.3 Cancer-causing viruses 1.2.4 Discovery of retrovirus Chapter 2. HIV/AIDS Drugs, Transforming a Death Sentence to a Chronic Disease 2.1 Discovery of the virus 2.1.1 A death sentence 2.1.2 Discovery of HIV and the great scientific controversy 2.1.3 The Nobel Prize 2.2 The first ray of hope 2.2.1 Nucleoside antiviral drugs 2.2.2 Non-nucleoside reverse transcriptase inhibitors 2.3 HIV protease inhibitors 2.3.1 HIV protease 2.3.2 First-generation HIV protease inhibitors 2.3.3 Second-generation HIV protease inhibitors 2.4 HIV integrase inhibitors 2.5 HIV Entry Inhibitors 2.5.1 HIV fusion inhibitors 2.5.2 CCR5 inhibitors 2.6 Triumph of modern medicine Chapter 3. Hepatitis Drugs 3.1 Hepatitis A virus 3.1.1 Discovery of hepatitis A virus 3.1.2 Hepatitis A vaccines 3.2 Hepatitis B virus 3.2.1 Discovery of hepatitis B virus 3.2.2 Hepatitis B vaccines 3.2.3 Hepatitis B drugs 3.3 Hepatitis C virus 3.3.1 Discovery of Hepatitis C virus 3.3.2 Hepatitis C virus NS3/4A protease inhibitors 3.3.3 Hepatitis C virus NS5A replication complex inhibitors 3.3.4 Hepatitis C virus NS5B polymerase inhibitors 3.4 Triumph of modern medicines Chapter 4. Influenza: A Perennial Killer 4.1 Influenza, a perennial killer 4.2 A virus that changed the world: the 1918 Spanish flu pandemic 4.3 Discovery of the influenza virus 4.4 Influenza vaccines 4.4.1 History of vaccination 4.4.2 History of influenza vaccines 4.4.3 Influenza vaccines today 4.5 Influenza drugs 4.5.1 M2 inhibitors 4.5.2 Influenza virus neuraminidase inhibitors 4.5.3 Cap-dependent endonuclease https://en.wikipedia.org/wiki/Ribonuclease inhibitor Chapter 5. Coronaviruses 5.1 Coronavirus Drugs 5.1.1. SARS 5.1.2. MARS 5.1.3. SARS-CoV-2 5.2 COVID-19 Vaccines 5.2.1. Pfizer/Biotech's mRNA vaccine 5.2.2. Johnson & Johnson's viral vector vaccine 5.3 COVID-19 Drugs 5.3.1. Remdesivir (Veklury) 5.3.2. Dexamethasone Chapter 6. Closing Remarks Bibliography Chemical Structures of Antiviral Drugs

Read more less

Book Synopsis

Read more less

Book SynopsisThis full-color, practical handbook provides a concise, evidence-based psychopharmacological approach to the management of complex treatment-resistant psychotic disorders. Part I focuses uniquely on topics and strategies relevant to treating this challenging patient population. These approaches go beyond standard guidelines while adhering to research and clinically derived data. Part II provides a concise array of information regarding those classes of medications most commonly used when treating complex treatment-resistant psychotic disorders. Each medication guide contains sections including mechanisms of action, typical treatment response, monitoring, dosing and kinetics, medications to avoid in combination/warnings, and take-home pearls. Part III offers tips in brief appendix chapters for managing common issues ranging from loading lithium and valproic acid to the treatment of acute psychomotor agitation. An essential resource for psychiatrists, forensic clinicians, psychiatric trainees, and all mental health professionals involved with, or interested in, the treatment of challenging psychotic disorders.Trade Review'The book is clearly useful for medical students, residents, and young psychiatrists.' Michael Easton, Doody's NotesTable of ContentsPart I. Treatment Strategies: 1.01. Approaches to positive Psychotic symptoms; 1.02. Use of plasma levels in Antipsychotic and Mood Stabilizer treatment; 1.03. Advantages of long-acting injectable Antipsychotics; 1.04. Approach to Schizophrenia Spectrum treatment-resistant patients; 1.05. Approach to depressed or suicidal Schizophrenia Spectrum patients; 1.06. Approach to persistent aggression and violence in Schizophrenia Spectrum Disorders; 1.07. Approach to treatment of Bipolar Diathesis in Schizophrenia Spectrum patients; 1.08. Approach to Anxiety in Schizophrenia Spectrum patients; 1.09. Approach to Insomnia and Sleep Disturbance in Schizophrenia Spectrum disorders; 1.10. Approach to Psychosis in children and adolescents; 1.11. Electro-convulsive therapy and other Non-pharmacological treatments; 1.12. Approach to substance use disorders in Schizophrenia Spectrum Disorders; 1.13. Approaches to Behavioral Disturbances and Dementia and TBI patients; Part II. Medication Reference Tables: First-generation (Typical) Antipsychotics: 2.01. Chlorpromazine; 2.02. Fluphenazine; 2.03. Haloperidol; 2.04. Loxapine; 2.05. Perphenazine; 2.06. Thiothixene; 2.07. Trifluoperazine; Second-generation (Atypical) Antipsychotics: 2.08. Asenapine; 2.09. Clozapine; 2.10. Iloperidone; 2.11. Lumateperone; 2.12. Lurasidone; 2.13. Olanzapine; 2.14. Paliperidone; 2.15. Quetiapine; 2.16. Risperidone; 2.17. Ziprasidone; Dopamine Partial Agonist Antipsychotics (Arias): 2.18. Aripiprazole; 2.19. Brexpiprazole; 2.20. Cariprazine; Medications for Motor/Neurologic Adverse Effects: 2.21. Amantadine; 2.22. Benztropine; 2.23. Diphenhydramine; 2.24. Trihexyphenidyl; Mood Stabilizers: 2.25. Carbamazepine; 2.26. Lamotrigine ; 2.27. Lithium; 2.28. Valproic Acid; Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants: 2.29. Citalopram; 2.30. Escitalopram; 2.31. Fluoxetine; 2.32. Fluvoxamine; 2.33. Paroxetine; 2.34. Sertraline: SSRI/5HT-1 Partial Agonist Antidepressants: 2.35. Vilazodone; 2.36. Vortioxetine; Serotonin/Norepinephrine Reuptake Inhibitor (SNRI) Antidepressants; 2.37. Desvenlafaxine; 2.38. Duloxetine; 2.39. Levomilnacipran; 2.40. Venlafaxine; Mixed Mechanism Antidepressants: 2.41. Bupropion; 2.42. Mirtazapine; 2.43. Trazodone; Tricyclic Antidepressants: 2.44. Amitriptyline; 2.45. Clomipramine; 2.46. Desipramine; 2.47. Doxepin; 2.48. Imipramine; 2.49. Nortriptyline; Monoamine Oxidase Inhibitor (MAOI) Antidepressants: 2.50. Isocarboxazid; 2.51. Moclobemide; 2.52. Phenelzine; 2.53. Transdermal Segeliline; 2.54. Tranylcypromine; Anxiolytics: 2.55. Alprazolam; 2.56. Buspirone; 2.57. Clonazepam; 2.58. Diazepam; 2.59. Hydroxyzine; 2.60. Lorazepam; Sedatives: 2.61. Diphenhydramine; 2.62. Eszopiclone; 2.63. Hydroxyzine; 2.64. Lorazepam; 2.65. Oxazepam; 2.66. Temazepam; 2.67. Zaleplon; 2.68. Zolpidem; Circadian Regulators: 2.69. Melatonin; 2.70. Ramelteon; 2.71. Tasimelteon; Stimulants: 2.72. Atomoxetine; 2.73. Dextroamphetamine; 2.74. Lisdexamphetamine; 2.75. Methylphenidate; 2.76. Mixed Amphetamine Salts: Histaminic Stimulants: 2.77. Armodafinil; 2.78. Modafinil; Cognitive Agents: 2.79. Dextromethorphan/quinidine; 2.80. Donepizil; 2.81. Galantamine; 2.82. Memantine; 2.83. Rivastigmine; Alpha2-adrenergic Agonists: 2.84. Clonidine; 2.85. Guanfacine; Appendices: 3.01. Optimal Antipsychotic Plasma Concentration Ranges; 3.02. Optimal Mood Stabilizer Plasma Concentration Ranges; 3.03. Formulas for QT Interval Correction; 3.04. Common Cytochrome P-450 Inducers and Inhibitors; 3.05. Management of Constipation; 3.06. Child-Pugh Hepatic Function Scoring; 3.07. Loading of Lithium and Valproic Acid; 3.08. Treatment of Prolactin Elevation; 3.09. A Select List of Foods High in Tyramine; 3.10. Medications that Present Risk for Serotonin Syndrome when Combined with MAOIs; 3.11. Selected Treatment of Psychomotor Agitation.

Read more less

Book SynopsisPopular among students and clinicians for its easy-to-read, case-study format, Winter’s Basic Clinical Pharmacokinetics, 7th Edition, clarifies complex concepts to help you confidently apply pharmacokinetics and therapeutic drug monitoring to patient care. This straightforward text is divided into two parts, reviewing basic pharmacokinetic principles in Part I and illustrating the clinical application of these principles to the most commonly encountered problems in Part II. The significantly updated and expanded 7th Edition adds essential coverage of the use of pharmacokinetics in managing obesity, pregnancy, as well as anticoagulation. NEW! Chapters unique to this 7th Edition equip students with proven pharmacokinetic approaches to obesity, pregnancy, and anticoagulation. Straightforward two-part format reinforces fundamental concepts and related clinical applications to ensure an advanced-level mastery. Case-based approach, similar to Applied Therapeutics, cultivates essential clinical reasoning capabilities. Detailed drug monographs familiarize students with the most commonly prescribed drugs for a wide range of problems and conditions.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisThis new selection of clinical stories, covers treatments that work, or fail, and mistakes made along the journey. Designed with a distinctive user-friendly presentation and making use of icons, questions/answers and tips, they address complex issues in an understandable way and with direct relevance to the everyday experience of clinicians.Table of ContentsIntroduction; List of icons; Abbreviations; 1. The case: achieving remission with medication management augmented with pet therapy; 2. The case: the luteal, jaw moving woman with paranoid paneling; 3. The case: the other lady with a moving jaw; 4. The case: the lady with MDD who bought an RV; 5. The case: the PCP who went the prescribing distance but came up short; 6. The case: intrusions, ammonia, and dyskinesias, oh my; 7. The case: the lady and the man who sat on couches; 8. The case: the lady who had her diagnosis altered; 9. The case: the man who picked things up; 10. The case: it worked this time, but with a hitch; 11. The case: the figment of a man who looked upon on the lady; 12. The case: the man who couldn't sell anymore; 13. The case: the woman who thought she was ill, then was ill; 14. The case: generically speaking, generics are OK; 15. The case: the woman who wouldn't leave her car; 16. The case: the woman who liked late night TV; 17. The case: the patient who interacted with everything; 18. The case: the angry twins; 19. The case: anxiety, depression, or prebipolaring?; 20. The case: the patient who wasn't lyming; 21. The case: hindsight is always 20/20 or ADHD; 22. The case: this one's too hot, this one's too cold… this one is just right; 23. The case: schizophrenia patient needs sleep; 24. The case: the man with greasy hands needs fine tuning; 25. The case: the combative business woman; 26. The case: the man with a little bit of everything; 27. The case: oops, he fell off the curve; 28. The case: 54-year-old with recurrent depression and 'psychiatric' Parkinsonism; 29. The case: 55-year-old with depression not responsive to serotonergic treatment; 30. The case: 23-year-old with first depression… that's it!; Index of drug names; Index of case studies.

Read more less

Trade Review"the definitive psychology text on willpower" --John Cloud, Time Magazine June 12 2006Table of ContentsForeword About the Editors 1: Self-Regulation: An Introductory Overview Part I: General Theories and Models of Self-Regulation 2: Attaining Self-Regulation: A Social Cognitive Perspective I INTRODUCTION II THE STRUCTURE OF SELF-REGULATORY SYSTEMS III SOCIAL AND ENVIRONMENTAL INFLUENCES ON SELF-REGULATION IV DYSFUNCTIONS IN SELF-REGULATION V DEVELOPMENT OF SELF-REGULATORY SKILL VI FUTURE RESEARCH DIRECTIONS VII A CONCLUDING COMMENT ACKNOWLEDGMENT 3: On the Structure of Behavioral Self-Regulation I BEHAVIOR IS GOAL DIRECTED AND FEEDBACK CONTROLLED II HIERARCHICALITY AMONG GOALS III FEEDBACK CONTROL AND CREATION OF AFFECT IV CONFIDENCE AND DOUBT, PERSISTENCE AND GIVING UP V DYNAMIC SYSTEMS AND HUMAN BEHAVIOR VI CATASTROPHE THEORY VII CONCLUDING COMMENT ACKNOWLEDGMENT 4: Aspects of Goal Networks: Implications for Self-Regulation I A STRUCTURAL ANALYSIS OF GOAL NETWORKS II SELF-REGULATORY CONSEQUENCES OF GOAL NETWORK STRUCTURE III INDIVIDUAL DIFFERENCES IN THE STRUCTURE OF GOALS AND MEANS IV COMPARISON TO OTHER PERSPECTIVES ON GOAL NETWORKS V FUTURE DIRECTIONS: INTERPERSONAL GOALS VI CONCLUSION 5: A Functional-Design Approach to Motivation and Self-Regulation: The Dynamics of Personality Systems Interactions I INTRODUCTION II DYNAMIC CONCEPTS IN CLASSICAL THEORIES OF MOTIVATION III ARISTOTLE’S DYNAMIC CONCEPTS IV PERSONALITY SYSTEMS INTERACTION THEORY V BACK TO THE FUTURE: FROM CONTENTS TO MECHANISMS VI CONCLUSION ACKNOWLEDGMENT 6: Personality, Self-Regulation, and Adaptation: A Cognitive–Social Framework I FRAMEWORKS FOR PERSONALITY AND SELF-REGULATION RESEARCH II SELF-REGULATION, TRAITS, AND COGNITIVE STRESS PROCESSES III PERSONALITY AND SELF-REGULATION OF REACTIONS TO LIFE STRESS IV PERSONALITY AND SELF-REGULATION IN PERFORMANCE ENVIRONMENTS V AGGRESSIVE BEHAVIOR VI CONCLUSIONS 7: Organization and Development of Self-Understanding and Self-Regulation: Toward a General Theory I INTRODUCTION II THE ARCHITECTURE OF SELF-AWARE AND SELF-REGULATED SYSTEMS III DEVELOPMENT OF SELF-UNDERSTANDING AND SELF-REGULATION IV EXPLAINING THE DEVELOPMENT OF SELF-UNDERSTANDING AND SELF-REGULATION V CONCLUSIONS 8: The Role of Intention in Self-Regulation: Toward Intentional Systemic Mindfulness I SYSTEMS THEORY, SELF-REGULATION, AND MINDFULNESS II SELF-REGULATION III SELF-REGULATION TECHNIQUES AND POTENTIAL LIMITATIONS IV PSYCHOPHYSIOLOGICAL RESEARCH ON SELF-REGULATION — PHYSIOLOGY AND ENERGY V ELABORATION OF AN EXPANDED SELF-REGULATION MODEL: INTENTION VI INTENTION VII INTENTIONAL SYSTEMIC MINDFULNESS: MINDFULNESS QUALITIES AND SYSTEMIC PERSPECTIVES VIII APPLICATIONS OF INTENTIONAL SYSTEMIC MINDFULNESS TO SELF-REGULATION TECHNIQUES IX CONNECTEDNESS AND INTERCONNECTEDNESS X GENERAL PRINCIPLES OF INTENTIONAL SYSTEMIC MINDFULNESS INTERVENTIONS XI FACILITATING INTENTION SYSTEMIC MINDFULNESS XII DIRECTIONS FOR FUTURE RESEARCH XIII IMPLICATIONS FOR HEALTH AND MEDICINE XIV SUMMARY ACKNOWLEDGMENTS 9: Communal Aspects of Self-Regulation I INTRODUCTION II COPING AS SELF-REGULATION III SUMMARY AND CONCLUSION ACKNOWLEDGMENT Part II: Domain-Specific Models and Research on Self-Regulation 10: Self-Regulation in Organizational Settings: A Tale of two Paradigms I INTRODUCTION II DEFINITIONS III TWO PARADIGMS IV THE PARADIGMS IN INDUSTRIAL– ORGANIZATIONAL PSYCHOLOGICAL THEORIES OF SELF-REGULATION V MERGING THE PARADIGMS VI CONCLUSION 11: Self-Regulation and Health Behavior: The Health Behavior Goal Model I INTRODUCTION II CURRENT HEALTH BEHAVIOR MODELS AND SELF-REGULATION III SELF-REGULATION AND THE PERSONAL GOAL STRUCTURE IV GOAL ALIGNMENT, GOAL CONFLICT, AND GOAL BALANCE V GOAL SETTING AND GOAL ORIENTATION VI GOALS, BELIEFS, AND EMOTIONS VII THE SELF-REGULATION PROCESS VIII THE HEALTH BEHAVIOR GOAL MODEL IX CONCLUSION AND DIRECTIONS FOR FUTURE RESEARCH ACKNOWLEDGMENT 12: Regulation, Self-Regulation, and Construction of the Self in the Maintenance of Physical Health I THE SELF-REGULATION THEME II PROBLEM SOLVING, SELF-REGULATION, AND REGULATION OF THE SELF III MODELING PROBLEM SOLVING, SELF-REGULATION, AND SELF-CONSTRUCTION IV ILLNESS COGNITION AND CONTROL THEORY V COPING PROCEDURES: GENERALIZED FACTORS VERSUS IF-THEN RULES THAT INTEGRATE REPRESENTATIONS, PROCEDURES, AND APPRAISALS VI THE SELF SYSTEM VII SUMMARY AND CONCLUDING COMMENTS ACKNOWLEDGMENT 13: Self-Regulated Learning: Finding a Balance Between Learning Goals and Ego-Protective Goals I INTRODUCTION II WHAT TURNS A POTENTIAL LEARNING OPPORTUNITY INTO A SITUATION THAT THE STUDENT IDENTIFIES AS SUCH? III SELF-REGULATED LEARNING ORIGINATES IN THE IDENTIFICATION, INTERPRETATION, AND APPRAISAL OF AN OPPORTUNITY TO LEARN IV GOAL SETTING: AN ESSENTIAL ASPECT OF SELF-REGULATED LEARNING V SELF-REGULATED LEARNING IMPLIES GOAL STRIVING VI CONCLUSIONS AND FUTURE DIRECTIONS 14: The Role of Goal Orientation in Self-Regulated Learning I A GENERAL FRAMEWORK FOR SELF-REGULATED LEARNING II GOAL ORIENTATION AND SELF-REGULATED LEARNING III CONCLUSIONS AND FUTURE DIRECTIONS FOR THEORY AND RESEARCH ACKNOWLEDGMENTS 15: Motivation and Action in Self-Regulated Learning I INTRODUCTION AND CONCEPTUAL FRAMEWORK II AN ACTION MODEL FOR THE PREDICTION OF LEARNING MOTIVATION III MOTIVATION, LEARNING, AND PERFORMANCE IV TWO AIMS FOR FURTHER RESEARCH ACKNOWLEDGMENTS 16: Measuring Self-Regulated Learning I MEASURING INTERVENES IN AN ENVIRONMENT II MEASUREMENTS OF SELF-REGULATED LEARNING REFLECT A MODEL OF SELF-REGULATED LEARNING III PROTOCOLS FOR MEASURING SELF-REGULATED LEARNING IV ISSUES IN MEASURING SELF-REGULATED LEARNING V CONCLUSIONS AND FUTURE DIRECTIONS ACKNOWLEDGMENT Part III: Interventions and Applications of Self-Regulation Theory and Research 17: Self-Regulation and Distress in Clinical Psychology I INTRODUCTION II SELF-REGULATION AND ADDICTIVE BEHAVIORS III SELF-REGULATION AND HEALTH IV SELF-REGULATION AND SOCIAL ANXIETY V SELF-REGULATION AND DEPRESSION VI SELF-REGULATION AND THERAPY VII SUMMARY AND CONCLUSIONS ACKNOWLEDGMENT 18: Self-Management of Chronic Illness I INTRODUCTION II CHARACTERISTICS OF CHRONIC ILLNESS III TREATMENT OF CHRONIC ILLNESS IV SELF-MANAGEMENT: SETTING THE STAGE V PROCESSES OF SELF-MANAGEMENT VI DISCUSSION VII FUTURE DIRECTIONS AND CONCLUSIONS 19: Self-Regulation and Academic Learning: Self-Efficacy Enhancing Interventions I INTRODUCTION II THEORETICAL FRAMEWORK III RESEARCH EVIDENCE IV INTERVENTIONS TO ENHANCE SELF-EFFICACY AND SELF-REGULATION V FUTURE RESEARCH ON SELF-REGULATION VI CONCLUSION 20: Teacher Innovations in Self-Regulated Learning I INTRODUCTION II OVERVIEW III STRATEGY INSTRUCTION RESEARCH IN THE CONTENT AREAS IV STRATEGY INSTRUCTION THROUGH COLLABORATIVE INNOVATION V DEVELOPING A MODEL FOR TEACHING SELF-REGULATED LEARNING THROUGH STORY VI COLLABORATIVE RESEARCH: FUTURE POSSIBILITIES VII SUMMARY 21: Self-Regulation: A Characteristic and a Goal of Mathematics Education I INTRODUCTION II LEARNING MATHEMATICS FROM INSTRUCTION: OUTLINE OF A THEORETICAL FRAMEWORK III STUDENTS’ FLAWS IN SELF-REGULATORY SKILLS AND BELIEFS IV FOSTERING STUDENTS’ SELF-REGULATION IN POWERFUL MATHEMATICS LEARNING ENVIRONMENTS 22: Self-Regulation Interventions with a Focus on Learning Strategies I HISTORICAL OVERVIEW II LEARNING STRATEGIES CAN BE MODIFIED OR LEARNED III THE NATURE OF STRATEGIES AND STRATEGY INSTRUCTION IV TYPES OF LEARNING STRATEGIES AND THEIR RELATIONSHIP TO OTHER STRATEGIC LEARNING COMPONENTS V MODEL OF STRATEGIC LEARNING VI TYPES OF STRATEGY INSTRUCTION AND THEIR EFFECTIVENESS VII IMPORTANT COMPONENTS OF ADJUNCT COURSES VIII THE NATURE AND IMPACT OF A COURSE IN STRATEGIC LEARNING AT THE UNIVERSITY OF TEXAS IX FUTURE DIRECTIONS FOR LEARNING STRATEGIES RESEARCH 23: Self-Regulation: Directions and Challenges for Future Research I DEVELOPING A TRACTABLE CONCEPTUAL FOUNDATION AND CONSISTENT NOMENCLATURE OF SELF-REGULATION CONSTRUCTS II CLARIFYING SELF-REGULATION STRUCTURE AND PROCESSES III MAPPING OUT THE NOMOLOGICAL NETWORK IV CONSTRUCTION OF MORE REFINED MODELS V REFINING MEASUREMENT OF SELF-REGULATION CONSTRUCTS VI IMPROVING RESEARCH METHODOLOGY VII EXPLORING INTERACTIONS BETWEEN ENVIRONMENT AND SELF-REGULATION VIII ACQUISITION AND TRANSMISSION OF SELF-REGULATORY SKILLS IX EXAMINING DEVELOPMENTAL DIFFERENCES IN SELF-REGULATORY SKILLS X EXAMINING INDIVIDUAL DIFFERENCES IN SELF-REGULATORY SKILLS XI APPLICATIONS XII TRAINING AND PROMOTION OF SELF-REGULATORY CONCEPTS Index

Read more less

Book SynopsisTrade ReviewAltered States genuinely moves forward in laying a path for new, insightful, and valuable information on the American Buddhism that is developing in our global society. D. E. Osto's groundbreaking research will be appreciated by scholars, and their accessible style will be enjoyed by nonacademic readers. -- Charles Prebish, author of Luminous Passage: The Practice and Study of Buddhism in AmericaAltered States deftly guides us through the neglected territory of psychedelic Buddhism. This is a fascinating story, full of vivid characters and supported by solid research. Still, I believe it makes a greater contribution by situating these practices and persons within the larger contexts of tantra, of American religion, and of cutting-edge neuropsychology and consciousness studies. The result is—to use le mot juste—mind blowing. -- Franz Metcalf, author of What Would Buddha Do?: 101 Answers to Life's Daily Dilemmas"[Altered States] mixes statistics and surveys, historical overview, personal experience, and ethnographic texture to uncover the intertwining history of two fast-growing movements in American spirituality.... This overview will appeal to anyone interested in Buddhism, psychedelic possibilities, and understanding how both are forging a controversial new American religious experience. * Publishers Weekly *Osto’s book is exceptional in its ability to focus the conversation about entheogens within religious perspectives. . . . They also point to more complex questions regarding the nature of subjectivity, experience, and scientific study. * Religious Theory *Of interest to anyone who wants to explore the intersection between traditional religion and altered states of consciousness, be they induced by psychedelics or any other means. * OPEN *Provocative.... The book is worth buying, reading, and quoting. * PsycCritiques *Table of ContentsPrefaceAcknowledgmentsIntroduction1. Buddhism and the Psychedelic Connection2. The Psychedelic Revolution3. The Buddhist Revolution4. Opening the Door: Psychedelics as a Gateway to Buddhist Practice5. Closing the Door: The Fifth Precept and Graduating from Psychedelics6. Keeping the Door Open: Psychedelics as an Adjunct to Buddhist Practice7. Are Psychedelics "the True Dharma"?: Debates, Presuppositions, and Philosophical IssuesConclusionsPostscriptNotesBibliographyIndex

Read more less

Book SynopsisProvides a comprehensive, literature-based but clinically oriented overview of the pervasive neurological adverse effects that frequently affect those receiving antipsychotic (and pharmacologically related) drugs, giving valuable information to the wide range of healthcare professionals who prescribe and monitor these extensively utilised therapeutic agents.Trade Review'This is an outstanding update of a very instructive book and should be mandatory reading for all trainees in psychiatry residency training programs - as well as their program directors … This book is like finding an oasis in a vast desert.' Doody's ReviewsTable of ContentsPreface; Part I. Setting the Scene: 1. The origins of psychopharma; 2. Some preliminaries; Part II. The Syndromes: 3. Acute dystonias; 4. Parkinsonism; 5. Akathisia; 6. Tardive dyskinesia; Part III. Particular Issues: 7. Tardive and chronic dystonia; 8. Special populations; Part IV. Assessment: 9. The clinical examination; 10. An overview of some standardised recording instruments; Part V. Matters Arising: 11. Involuntary movements and schizophrenia: a limitation to the concept of tardive dyskinesia?; 12. And finally … the salutary tale of 'atypicality'; References; Index.

Read more less

Book SynopsisThis spin-off from Stephen M. Stahl's new, completely revised, and fully updated sixth edition of the Prescriber's Guide covers the most important drugs in use today for treating depression.Table of ContentsIntroduction; List of icons; Agomelatine; Amisulpride; Amitriptyline; Amoxapine; Amphetamine (d); Amphetamine (d,l); Aripiprazole; Armodafinil; Asenapine; Atomoxetine; Brexpiprazole; Bupropion; Buspirone; Citalopram; Clomipramine; Cyamemazine; Desipramine; Desvenlafaxine; Dothiepin; Doxepin; Duloxetine; Escitalopram; Fluoxetine; Flupenthixol; Fluvoxamine; Iloperidone; Imipramine; Isocarboxazid; Ketamine; Lamotrigine; Lisdexamfetamine; Lithium; Lofepramine; Lurasidone; Maprotiline; Methylfolate (l); Methylphenidate (d); Methylphenidate (d,l); Mianserin; Milnacipran; Mirtazapine; Moclobemide; Modafinil; Nefazodone; Nortriptyline; Olanzapine; Paroxetine; Phenelzine; Protriptyline; Quetiapine; Reboxetine; Selegiline; Sertindole; Sertraline; Sulpiride; Tianeptine; Tranylcypromine; Trazodone; Triiodothyronine; Trimipramine; Venlafaxine; Vilazodone; Vortioxetine; Index by drug name; Index by use.

Read more less

Book Synopsis

Read more less

Book Synopsis

Read more less

Book SynopsisIn recent years, a dedicated effort has been made to understand the immune dysfunction that is associated with major psychiatric disorders. The expanding knowledge of the immune system as a major homeostatic system has been very helpful in indicating new potential biomarkers and therapeutic targets to reduce the burden of psychiatric disorders. Indeed, immune cells, their secreted molecules, and cell signalling events are highly promising. Yet, the literature on immunology of psychiatric disorders is still dispersed, and only a few attempts have been made to consolidate the current knowledge in this expanding area.This book assembles and presents the available data on the immune/inflammatory dysfunction in psychiatric disorders, indicating the potential of immune mechanisms as either biomarkers or therapeutic targets, as well as discussing the challenges ahead of incorporating this knowledge into clinical practice. An international team of senior experts in the field review all psychiatric disorders in order to provide an integrated, in-depth understanding of the role of immune changes in psychiatric diseases for mental health clinicians as well as for researchers in immunology, psychiatry, neurology, and pharmacology.Table of ContentsChapter 1: Overview of the immune system Chapter 2: Immune-neuropharmacology Chapter 3: Immune mechanisms affecting CNS functioning Chapter 4: Immune mechanisms and CNS development Chapter 5: The immune system as a sensor capable to affect other homeostatic systems Chapter 6: Microbiota-Gut-Brain Axis and Neuropsychiatric Disorders Chapter 7: Investigating immune changes in the psychiatric patient Chapter 8: Immune dysfunction: a common feature of major psychiatric disorders? Chapter 9: Immunology of substance use disorder Chapter 10: Immune system dysregulation and schizophrenia Chapter 11: Depression as a neuroinflammatory condition Chapter 12: Immunology of bipolar disorder Chapter 13: immunology of post-traumatic stress disorder (PTSD) Chapter 14: Immunology of eating disorders Chapter 15: Immunology of late-life psychiatric disorders and dementias Chapter 16: Immune-based biomarkers and therapies in psychiatry: future prospects

Read more less

Book SynopsisIntroduction to Neuropsychopharmacology expands on the molecular and cellular foundations of the classic Biochemical Basis of Neuropharmacology, Eighth Edition (Cooper, Bloom, and Roth) by now including the behavioral methods used to study psychoactive drugs in experimental animals and in humans. Authored by four founders of modern neuroscience, this concise and comprehensive text covers the current series of medications used to treat diseases of the brain and nervous system--both psychiatric and neurologic--as well as legal and illegal recreational drugs and the neuroscientific information that explains how these medications act on the brain from the molecular to the clinical level. The text ranges from drugs that affect the mood and behavior to hypnotics, narcotics, anticonvulsants, and analgesics.Trade ReviewThis informative and readable new introductory textbook should be required reading for any medical student, graduate student, or physician interested in understanding neuroscience...an outstanding learning tool. * Doody's Notes *Table of ContentsCONTENTS; CONTRIBUTORS

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

a huge range and FREE tracked UK delivery on ALL orders.

Read more less

Book SynopsisA challenging reappraisal of the history of antipsychotics, revealing how they were transformed from neurological poisons into magical cures, their benefits exaggerated and their toxic effects minimized or ignored.Trade Review"This book will make an enormous contribution towards a more rational, transparent and ethical approach to the use of neuroleptic drugs. By implication it also offers up a strong argument for much wider choice for people in crisis, particularly the provision of minimal drug/drug-free systems of help and support, such as Soteria-type facilities and Open Dialogue. It is a must-read for all psychiatrists and mental health professionals, and its accessibility means that many survivors/service users and carers will find it a valuable ally in their fight for more humane and less harmful alternatives to psychiatric drug treatment." - Philip Thomas, University of Bradford, UK 'a meticulous, balanced history of antipsychotic drugs' - Nature 'All in all, this is a brilliantly clear-eyed, informative, well-referenced and at times disturbing book which should be essential reading for clinicians, policy-makers and patients alike.' - Psychosis: Psychological, Social and Integrative Approaches 'Joanna Moncrieff's courageous research continues to point out that the emperor, while dressed, is wearing the wrong clothes for the job.' - Therapy Today 'Psychiatrist Moncrieff [...] offers a refreshingly critical look at the motivation behind atypical antipsychotic drug use from the pharmaceutical standpoint as well as the pharmacological basis, or lack thereof, in some cases.' - Choice 'This schematic account cannot do justice to the tightness of the arguments and numerous illustrative examples with which Dr Moncrieff charts the all-important transition from the drug-centred to the disease-centred model and its adverse consequences.' - BrainTable of ContentsPreface 1. Cure or Curse? 2. Chlorpromazine 3. Magic Bullets 4. Building a House of Cards 5. The Phoenix Rises 6. Looking Where the Light is 7. The Patient's Dilemma 8. Antipsychotics as Chemical Cosh 9. Old and New Drug-Induced Problems 10. The First Tentacles 11. The Antipsychotic Epidemic 12. All is Not as it Seems

Read more less